Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
...TK). In preclinical studies, BAY 73-4506 has been shown to inhibit tumor growth by hitting targets along a spectrum of angiogenic pathways, including vegfr
and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell dea...
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
-- Unique enzymatic profile of a potent and selective BEGFR/PDGFR tyrosine kinase inhibitor, TAK-593: potent pseudo-irreversibility against vegfr
and PDGFR -- Lead investigator: H. Miki, Takeda Pharmaceutical Company, Japan -- Abstract #50: Poster
-- TAK-593, a potent and selectiv...
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
...24 /PRNewswire-FirstCall/ -- Exelixis, Inc.
(Nasdaq: EXEL ) today reported updated data from a phase 2 study of XL647,
an inhibitor of EGFR, HER2 and vegfr
kinases, in previously untreated,
clinically selected non-small cell lung cancer (NSCLC) patients. The data
continue to show encouraging anti-tumor ac...
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
...stCall/ -- Exelixis, Inc.
(Nasdaq: EXEL ) today reported encouraging data from an ongoing phase 1
trial of XL184, a potent inhibitor of MET, RET, and vegfr
patients with advanced solid tumors or lymphoma. Anti-tumor activity has
been observed in a variety of cancers at doses that are not assoc...
New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
...se-escalation study of the safety and pharmacokinetics (PK) of XL184, a vegfr
and MET kinase inhibitor, administered orally to patients (pts) with ad...y of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a vegfr
and MET kinase inhibitor, administered daily to patients (pts) with adv...
Ascenta Therapeutics Highlights Multiple Data Presentations at
Upcoming AACR Annual Meeting
...orally active pan-Bcl-2 family Zhang, MD,
protein inhibitor in combination PhD
with dual-Raf/MEK and vegfr
kinase inhibitor sorafenib Therapeutics
--------- --------- ----------...
New Data Show Pfizer's Axitinib Prolonged Overall Survival in
Advanced Pancreatic Cancer When Combined with Standard of Care
axitinib (AG-013736), an investigational oral, selective inhibitor
1, 2,3 (vascular endothelial growth factor receptors 1, 2,
3) combined with...t
Axitinib is an oral, selective inhibitor of vegfr
1, 2, 3
(vascular endothelial growth factor receptors 1, 2 and 3), which
Telik Reports Preclinical Results at AACR Annual Meeting
...echanism of Action of Orally Active Aurora Kinase/ vegfr
Inhibitors; Abstract # 1764
Aurora kinases are ...ong and equipotent inhibition of Aurora kinase and vegfr
kinase, with IC50s less than 10 nM.
Drug inhibition of aurora kinase and vegfr
activity in tumor samples of treated animals was e...
Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
... PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK ) announced today that the lead compounds of its Aurora kinase
dual inhibitor program met a significant development milestone.
Aurora kinase is a critical signaling enzyme whose function is required for